Table 2. Effects of ERK1/2 and STAT3 inhibitors on cell death (A) and cell proliferation (B) in HepG2 cells.
| A. | Cell death (CD) and supra-additivity of Sf and CA effects | Comparisons between treatment groups | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HepG2 | 1. Mean | 2. SD | 3. Net | 4. P values | 5. | 6. Comparison | 7. Comparison | 8. Comparison | 9. Comparison | |
| n = 9 | CD | CD | CD | vs Control | Supra-additivity | vs Control | vs Sf only | vs CA only | vs Sf+CA | |
| 1 | Control--24 hr | 9.9% | 3.0% | vs G1 | vs G1 | Based on net CD | G1–G2 = –6.0% | |||
| 2 | Sf-1 uM | 15.9% | 3.1% | 6.0% | 0.013 | G4–(G2+G3) | p = 0.013 | |||
| 3 | CA-10 uM | 12.2% | 2.6% | 2.3% | 0.059 | 23.3%–(6.0%+2.3%) | ||||
| 4 | Sf-CA | 33.2% | 4.6% | 23.3% | 0.001 | 15.0% | ||||
| 5 | U0126-1 uM | 11.8% | 3.7% | vs G5 | vs G5 | G5–G1 = 1.9% | G6–G2 = 3.8% | |||
| 6 | U0126-Sf | 19.7% | 3.6% | 7.9% | 0.012 | G8–(G6+G7) | p = 0.265 | p = 0.018 | G7–G3 = 6.2% | |
| 7 | U0126-CA | 18.4% | 3.9% | 6.6% | 0.001 | 21.9%–(7.9%+6.6%) | p = 0.002 | G8–G4 = 0.4% | ||
| 8 | U0126-Sf-CA | 33.7% | 3.5% | 21.9% | 0.001 | 7.4% | p = 0.836 | |||
| 9 | Stattic-20 uM | 14.2% | 3.2% | vs G9 | vs G9 | G9–G1 = 4.3% | G10–G2 = 11.9% | |||
| 10 | Stattic-Sf | 27.8% | 3.2% | 13.6% | 0.001 | G12–(G10+G11) | p = 0.015 | p = 0.001 | G11–G3 = 11.2% | |
| 11 | Stattic-CA | 23.4% | 4.0% | 9.2% | 0.002 | 34.4%–(13.6%+9.2%) | p = 0.001 | G12–G4 = 14.9% | ||
| 12 | Stattic--Sf-CA | 48.6% | 4.1% | 34.4% | 0.003 | 11.5% | p = 0.004 | |||
| B. | Cell proliferation (CP) and supra-additivity of Sf and CA effects | Comparisons between treatment groups | ||||||||
| HepG2 | 1. Cell number | 2. Increase | 3. Increase | 4. P values | 5. | 6. Comparison | 7. Comparison | 8. Comparison | 9. Comparison | |
| Base = 148k/mL, n = 7 | Mean (k/mL) | over Base | SD | vs CTL | Supra-additivity | vs Control | vs Sf only | vs CA only | vs Sf+CA | |
| 1 | Control-24 hr | 240.7 | 62.6% | 9.2% | vs G1 | Based on % increase | G1–G2 = –14.5% | |||
| 2 | Sf-1 uM | 219.3 | 48.2% | 10.8% | 0.004 | G4–(G2+G3) | p = 0.004 | |||
| 3 | CA-10 uM | 237.1 | 60.2% | 7.8% | 0.937 | 23.3%–(48.2%+62.6%) | ||||
| 4 | Sf-C | 182.5 | 23.3% | 7.5% | 0.006 | –85.1% | ||||
| 5 | U0126-1 uM | 217.1 | 46.7% | 6.3% | vs G5 | G5–G1 = –15.9% | G6–G2 = –25.6% | |||
| 6 | U0126-Sf | 181.4 | 22.6% | 8.0% | 0.002 | G8–(G6+G7) | p = 0.005 | p = 0.002 | G7 -G3 = -36.3% | |
| 7 | U0126-CA | 184.6 | 24.8% | 8.0% | 0.002 | 3.0%–(22.6%+24.8%) | p = 0.001 | G8–G4 = –20.9% | ||
| 8 | U0126-Sf-CA | 152.5 | 3.0% | 7.7% | 0.001 | –44.3% | p = 0.001 | |||
| 9 | Stattic-20 uM | 241.8 | 63.4% | 10.5% | vs G9 | G9–G1 = 0.7% | G10–G2 = –14.0% | |||
| 10 | Stattic-Sf | 198.6 | 34.2% | 6.6% | 0.001 | G12–(G10+G11) | p = 0.927 | p = 0.009 | G11–G3 = –32.7% | |
| 11 | Stattic-CA | 190.0 | 28.4% | 5.3% | 0.001 | 1.1%–(34.2%+28.4%) | p = 0.001 | G12–G4 = –23.1% | ||
| 12 | Stattic-Sf-CA | 149.6 | 1.1% | 5.4% | 0.001 | –61.5% | p = 0.001 | |||
HepG2 cells. (A) The percent of dead cells (CD) was determined and calculated as detailed in the legend to Table 1. (B) Cell proliferation (CP) was determined and calculated as detailed in the legend to Table 1. The data are means ± SD of three independent experiments performed in triplicate, n = 9.